<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02625714</url>
  </required_header>
  <id_info>
    <org_study_id>SID142_BE_I_2015</org_study_id>
    <nct_id>NCT02625714</nct_id>
  </id_info>
  <brief_title>Safety/Tolerability and Pharmacokinetic Study of SID142</brief_title>
  <official_title>A Randomized, Open-label, Oral Multiple Dosing, Two-way Crossover Clinical Trial to Evaluate the Safety/Tolerability and Pharmacokinetic Profiles of SID142 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Chemicals Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Chemicals Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, oral multiple dosing, two-part, two-way crossover clinical trial to
      evaluate the safety/tolerability and pharmacokinetic profiles of SID142 in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC[Area under the concentration curve]τ,ss of Cilostazol</measure>
    <time_frame>During 144hours post-dose in each period</time_frame>
    <description>Total 68 time points during periods of both 1 and 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss of Cilostazol</measure>
    <time_frame>During 144hours post-dose in each period</time_frame>
    <description>Total 68 time points during periods of both 1 and 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUClast,ss of Cilostazol</measure>
    <time_frame>During 144hours post-dose in each period</time_frame>
    <description>Total 68 time points during periods of both 1 and 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss of Cilostazol</measure>
    <time_frame>During 144hours post-dose in each period</time_frame>
    <description>Total 68 time points during periods of both 1 and 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL[clearance]SS/F of Cilostazol</measure>
    <time_frame>During 144hours post-dose in each period</time_frame>
    <description>Total 68 time points during periods of both 1 and 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of Cilostazol</measure>
    <time_frame>During 144hours post-dose in each period</time_frame>
    <description>Total 68 time points during periods of both 1 and 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of Adverse Events</measure>
    <time_frame>During 25days from first administration of period 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Arterial Occlusive Diseases</condition>
  <arm_group>
    <arm_group_label>A group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Renexin® → SID142</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>SID142 → Renexin®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Renexin®</intervention_name>
    <description>Cilostazol 100mg/ginko biloba leaf extract 80mg, Immediate release, bid</description>
    <arm_group_label>A group</arm_group_label>
    <arm_group_label>B group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SID142</intervention_name>
    <description>Cilostazol 200mg/ginko biloba leaf extract 160mg, Controlled release, qd</description>
    <arm_group_label>A group</arm_group_label>
    <arm_group_label>B group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult aged between 19 and 45

          2. Weights more than 50Kg , BMI between 18.5 and 25.0 kg/m2

          3. Subject without congenital or chronic disease requiring medical treatment and any
             pathological symptoms or opinion according to internal examination

          4. Subject with acceptable laboratory result and ECG result

          5. Negative result to blood serum human chorionic gonadotropin[hCG] pregnancy test at
             screening and urine hCG pregnancy test prior to administration in female subject. In
             addition, at least one condition should be corresponded which is stated below

               -  Menopause(no menstruation for at least 2 years)

               -  surgically sterile (hysterectomy or both oophorectomy, tubal ligation or other
                  method)

               -  Male partner should be sterile(confirmed as aspermia after deferentectomy) and
                  sole before screening.

               -  Woman who agreed to use proper method of conception accurately and continuously
                  from at least 14 days before first Investigational Product[IP] administration to
                  at least 30days after dosing.

          6. Male subject should use contraception(condom) during clinical trial and maintain
             contraception and agree not to donate sperm until 28days after last dosing.

          7. Subject who was given and completely understood full explanation about the study,
             decided to participate in the study and signed written informed consent willingly.

        Exclusion Criteria:

          1. Female subject who is pregnant or breast-feeding

          2. Person who has anaphylaxis for IP component or clinically significant medical history
             of anaphylaxis for other drugs

          3. Subject with a clinically significant medical history of disease on liver, kidney,
             nervous system, respiratory system, endocrine system, blood tumor, urinary system,
             cardiovascular system, musculoskeletal system or psychiatric disorder or others below

               -  severe nephrotic disorder

               -  moderate or severe hepatic disorder

               -  menstruation period

               -  aortocoronary stenosis complication

               -  disease or predisposition of bleeding

               -  congestive heart failure or arrhythmia

               -  diabetes mellitus or glucose tolerance disorder

          4. Subject with clinically significant findings on electrocardiogram[ECG] result during
             screening as stated below

               -  QTc &gt; 450 ms

               -  PR interval &gt; 200 msec

               -  QRS duration &gt; 120 msec

          5. Active liver disease or inadequate laboratory result: AST[aspartate aminotransferase]
             , ALT[alanine aminotransferase] &gt; 1.5 x upper limit of normal range

          6. At screening, subject with clinically significant vital signs(sitting position blood
             pressure): Systolic blood pressure &gt;140 mmHg or &lt; 90 mmHg, diastolic pressure &gt; 90
             mmHg or &lt; 60 mmHg

          7. Hereditary galactose intolerance, Lapp lactase deficiency or glucose-galactose
             malabsorption syndrome

          8. Subject with a presence of gastroenteric disease or history of gastroenteric surgery
             which can influence the drug absorption

          9. Subject who has been seriously injured or received surgery or shown suspicious acute
             disease symptoms within 4 weeks of first administration.

         10. Consumption of excessive alcohol continuously or the subject who cannot quit drinking
             within 3 days prior to IP administration and during clinical trial period or subject
             who smokes

         11. A history of taking any ETC drugs[Ethical drugs], oriental medicine within 2 weeks or
             OTC drugs[Over-the-Counter drugs] within 1week prior to first administration

         12. Participation in another clinical trial in the previous 3 months before first
             administration of this study

         13. Donation of whole blood in the previous 2 months or apheresis blood in the previous 1
             month before first administration

         14. The subject with abnormal diet which can influence absorption, distribution,
             metabolism, and excretion of drug

         15. Consumption of food which can influence drug metabolism or caffeine within 48 hours
             after the first administration, or the subject who cannot quit consumption of such
             foods during whole study period.

         16. Positive results to serum tests (HBsAg[hepatitis B surface antigen], anti-HCV
             Ab[hepatitis C virus antibody], anti-HIV Ab[human immunodeficiency virus antibody],
             VDRL[Venereal Disease Research Laboratory] test)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Kyu Park, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dong-A University Hospital</affiliation>
  </overall_official>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2015</study_first_submitted>
  <study_first_submitted_qc>December 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2015</study_first_posted>
  <last_update_submitted>December 10, 2015</last_update_submitted>
  <last_update_submitted_qc>December 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

